Ketamine Troches vs. Nasal Spray: Compounded and Brand-Name Options

Three Nasal and Oral Routes for Ketamine

Patients exploring ketamine therapy encounter three distinct options in the nasal/oral delivery category: compounded ketamine troches, compounded ketamine nasal spray, and FDA-approved esketamine nasal spray (Spravato). Though all three deliver a form of ketamine without needles, they differ significantly in their active molecule, regulatory status, cost, access requirements, and clinical evidence.

The Molecular Distinction: Ketamine vs. Esketamine

This is perhaps the most important distinction patients often don't realize:

Racemic ketamine (used in troches and compounded nasal spray) is a 50/50 mixture of two mirror-image molecules: R-ketamine and S-ketamine. Both enantiomers are pharmacologically active, with distinct receptor binding profiles and potentially distinct therapeutic properties. R-ketamine may have antidepressant effects through different mechanisms than NMDA receptor antagonism alone.

Esketamine (Spravato) contains only S-ketamine — the purified S-enantiomer. S-ketamine is approximately twice as potent at NMDA receptors as R-ketamine, meaning lower absolute doses produce equivalent NMDA blockade. Esketamine was developed as a distinct pharmaceutical product, separate from racemic ketamine, and its approval required its own clinical trial program.

Some researchers believe the combination of both enantiomers in racemic ketamine produces therapeutic effects that pure esketamine cannot fully replicate. Our article on active ingredients in ketamine troches explains the racemic vs. enantiomer distinction in more detail. This remains an open scientific question.

Compounded Ketamine Nasal Spray

What It Is

Compounded ketamine nasal spray is a solution of racemic ketamine HCl in a buffered saline or other appropriate vehicle, prepared by a compounding pharmacy and delivered via a nasal atomizer. It is prescribed by a licensed provider and compounded under 503A or 503B frameworks — the same regulatory basis as troches.

Bioavailability

Nasal mucosa is among the most permeable mucosal surfaces in the body, with rich vascularity directly accessible from the nasal cavity. Intranasal bioavailability of ketamine from compounded sprays ranges from approximately 25 to 50 percent — generally higher than sublingual troches (20 to 30%) and potentially faster in onset.

However, intranasal absorption is significantly affected by:

• Nasal congestion (common cold, allergies): can reduce absorption by 30 to 50 percent
• Mucosal irritation from repeated use
• Proper spray technique (angling the device, breathing in during administration)

Onset and Duration

• Onset: 5 to 15 minutes (faster than troches)
• Duration: 30 to 60 minutes of significant effects (shorter than troches)

Cost

Compounded ketamine nasal spray is comparable in cost to troches: approximately $100 to $300 per month for medication, with similar provider fees.

Access and Administration

Compounded nasal spray is patient-administered at home. No clinic visit is required for administration. However, the technique is somewhat sensitive — incorrect administration reduces bioavailability significantly.

FDA-Approved Esketamine (Spravato)

What It Is

Spravato is FDA-approved esketamine nasal spray, manufactured by Janssen Pharmaceuticals. It is approved for:

• Treatment-resistant depression (TRD) in adults
• Major depressive disorder with acute suicidal ideation or behavior (MDD-SI), in conjunction with an oral antidepressant

Unlike compounded options, Spravato has undergone extensive Phase 2 and Phase 3 clinical trials demonstrating efficacy and safety.

Bioavailability

Spravato delivers esketamine intranasally with approximately 48 percent bioavailability. It is designed with a calibrated nasal spray device (2 sprays per device, 28 mg per spray, 56 mg total per device) to ensure consistent delivery.

The REMS Program: A Critical Difference

Spravato is subject to a Risk Evaluation and Mitigation Strategy (REMS) program, which means:

• Spravato cannot be taken at home: Every administration must occur in a certified healthcare setting (a Spravato-certified outpatient clinic or treatment center)
• Patients must be monitored for at least 2 hours after each dose in the certified facility
• Patients cannot drive on session days

This monitoring requirement makes Spravato logistically similar to IV ketamine — requiring clinic visits and transportation — despite being a nasal spray rather than an injection.

Dosing Protocol for Spravato

• Acute phase: 56 mg or 84 mg twice per week for 4 weeks
• Maintenance phase: Once weekly for 4 weeks, then once weekly or once every two weeks

Insurance Coverage

Spravato's FDA approval means it is more likely than compounded options to receive insurance coverage. Some commercial insurers and Medicare cover it for appropriate diagnoses, though prior authorization requirements are common and not all patients qualify under insurer criteria.

Cost

At list price, Spravato costs approximately $590 to $900 per device (two devices may be needed per session for the 84 mg dose), making a full acute course of treatment extraordinarily expensive without insurance. With insurance coverage, patient out-of-pocket costs vary widely from minimal (with manufacturer coupons) to several thousand dollars per month.

Head-to-Head Comparison: Troche vs. Compounded Nasal vs. Spravato

Clinical Efficacy Considerations

Spravato has the strongest regulatory evidence — it was approved based on randomized controlled trials. However, multiple systematic reviews and meta-analyses have concluded that racemic IV ketamine has at least equivalent if not superior antidepressant efficacy compared to esketamine, likely due to the contribution of R-ketamine.

For compounded sublingual troches specifically, the evidence base is smaller. But clinical experience from thousands of outpatient patients suggests efficacy comparable to lower-dose IV and IM protocols when doses are appropriately calibrated.

Choosing Spravato primarily for its FDA approval status, while ignoring the monitoring burden and cost, may not result in better outcomes for an individual patient compared to a well-managed troche program.

Which Option Is Right for You?

Choose Spravato if:

• You have TRD or MDD-SI and your insurer covers it
• You value the FDA-approved evidence base and professional monitoring during sessions
• You have access to a Spravato-certified clinic and transportation
• You are not a candidate for home-based therapy

Choose compounded nasal spray if:

• You want faster onset than troches but prefer home administration
• You don't have significant nasal congestion or mucosal issues
• Your provider prefers this formulation for your specific situation

Choose troches if:

• You want the longest session duration for extended therapeutic processing
• Swallowing or nasal issues make other routes impractical
• Cost is a primary concern
• You value the comfort and flexibility of home administration with a longer experience arc

Key Takeaways

• Troches use racemic ketamine; Spravato uses S-ketamine only — these are pharmacologically distinct.
• Compounded nasal spray offers faster onset and somewhat higher bioavailability than troches, but shorter duration.
• Spravato requires in-clinic administration with 2-hour monitoring; home use is not permitted.
• Spravato has the strongest regulatory approval; compounded options have less formal evidence but broad clinical use.
• Cost and insurance coverage differ dramatically between options.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• MedlinePlus: Esketamine Nasal Spray — National Library of Medicine drug information on FDA-approved Spravato (esketamine) for treatment-resistant depression
• FDA: Approved Drug Products — U.S. Food and Drug Administration searchable database of approved drug products and therapeutic equivalents